406-5 Oxidized low-density lipoprotein-stimulated smooth muscle cell growth is mediated by the helix loop helix factor Id3: A novel mechanism contributing to atherosclerotic lesion formation  by Taylor, Angela M et al.
534A ABSTRACTS - Young Investigators Awards JACC March 3, 2004
Yo
un
g 
In
ve
st
ig
at
or
s 
Aw
ar
ds
cytoskeleton reorganization and cell shape changes in terms of lamellipodia formation in
KO VSMCs compared with WT VSMCs.
Conclusions: These findings suggest that CHF1/Hey2 is an important
regulator of VSMC motility during vascular remodeling through control of PDGF and HB-
EGF dependent signaling pathways.
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406-5 Oxidized Low-Density Lipoprotein-Stimulated Smooth 
Muscle Cell Growth Is Mediated by the Helix Loop Helix 
Factor Id3: A Novel Mechanism Contributing to 
Atherosclerotic Lesion Formation
Angela M. Taylor, Feng Li, Ross Gerrity, Richard L. Birnbaum, Martin Matsumura, Sarah 
Rutherford, Puspha-Rekha Thimmalapura, Coleen A. McNamara, University of Virginia, 
Charlottesville, VA
Background: Oxidation of LDL has emerged as the initiating event in cardiovascular
lesion formation. Little is known about the molecular mechanisms linking Ox-LDL and
vascular smooth muscle cell accumulation, the harbinger of vascular lesion progression.
The HLH transcription factor Id3 is a redox sensitive gene that is expressed in VSMC in
response to mitogen stimulation and vascular injury. Id3 is a regulator of growth and dif-
ferentiation in several other cell types. Accordingly we hypothesize that Id3 is an impor-
tant mediator of Ox-LDL-induced VSMC growth.
Methods: Primary vascular smooth muscle cells were infected with AdId3 or AdGFP
control and assayed for cell number, BrdU incorporation and p21cip1 expression by West-
ern blot analysis. Parallel cultures were stimulated with Ox-LDL or nLDL or sera from
hyperlipemic, atherosclerotic pigs or normolipemic pigs without vascular lesions.
Results: Results demonstrated that increasing Id3 expression in VSMC decreased
p21cip1 expression and increased BrdU incorporation and cell number. Cotransfection
with pAdId3 and p21cip1 promoter-luciferase reporter construct demonstrated that Id3
regulates p21cip1 promoter activation in VSMC. Ox-LDL and hyperlipemic porcine sera
increase Id3 protein expression and VSMC proliferation. Consistent with the role of Id3
as an inhibitor of p21cip1 expression, infection with pAdId3 increased BrdU incorporation
and increased cell number. Stimulation with hyperlipemic sera increased cell number and
S-phase entry. Furthermore, aortas of hyperlipemic pigs demonstrated significantly more
Id3 than normolipemic controls.
Conclusion: The HLH factor Id3 mediates the mitogenic effect of hyperlipemic sera and
Ox-LDL in VSMC via inhibition of p21cip1 expression and inhibition of DNA synthesis.
Moreover, hyperlipemic, atherosclerotic animals express greater amounts of Id3 protein
in the vessel wall than normolipemic controls providing the first in vivo evidence implicat-
ing Id3 as an important mediator of atherogeneis.
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408-1 Genetic Polymorphism G894T on Endothelial Nitric 
Oxide Synthase Gene as a Risk Factor for Premature, 
Nonfatal Myocardial Infarction in Young Male Smokers
Charalambos Antoniades, Dimitris Tousoulis, Christos Pitsavos, Carmen Vasiliadou, 
Christina Chrysochoou, Marina Toutouza, Demosthenis Panagiotakos, Costas 
Tentolouris, Pavlos Toutouzas, Christodoulos Stefanadis, Athens University Medical 
School, Cardiology Department, Hippokration Hospital, Athens, Greece
Background. Endothelial nitric oxide synthase (eNOS) gene polymorphism G894T has
been associated with arterial hypertension and myocardial infarction (MI) in older ages.
However, its role in the pathogenesis of premature MI remains unclear. We investigated
whether this polymorphism is associated with premature non-fatal MI.
Methods. This case-control study enrolled 212 young patients with premature non-fatal
MI (aged 46.5±5.2 years old) and 577 healthy age- matched controls (aged 48.1±13.5
years old), derived from ATTICA cohort. Polymerase chain reaction was done to detect
G894T polymorphism on the eNOS gene. X2 was used to test the significance of an
association between eNOS genotype and the presence of premature MI (under the age
of 50).
Results. Homozygosity for the 894T allele, existed in 27 MI patients (13%) and in 58
(10.1%) controls (p=0.281). The frequency of T allele was 0.552 among cases and 0.518
among controls (p= 0.126). In comparison to 894G homozygotes, the odds ratio for MI
was 1.406(95%CI: 0.843 to 2.347, p= 0.191) for 894T homozygotes and 1.172 (95%CI:
0.837 to 1.64, p=0.355) for heterozygotes respectively. However, among male smokers,
homozygosity for this polymorphism was observed in 23 of 179 MI cases (12.8%) and
only in 7 of 157 controls (4.5%) (p=0.008). Among male smokers, the odds ratio for MI in
TT homozygotes was 3.367 (95%CI: 1.369 to 8.279, p= 0.006) compared to GG, 2.935
(95%CI: 1.184-7.277, p=0.017) compared to GT and 3.159 (95%CI:1.317-7.581,
p=0.007) compared to GG+GT. However, no association between G894T polymorphism
and premature MI was observed in male non-smokers and in female smokers or non-
smokers.
Conclusions. The present study supports that G894T polymorphism on eNOS gene
may interact with smoking leading to premature, non-fatal myocardial infarction in young
males.
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408-2 Cardiac Troponin Elevations in Marathon Runners: 
Prevalence and Risk Factors
Elizabeth B. Fortescue, Andrew Y. Shin, David S. Greenes, Rebekah Mannix, Nader 
Rifai, Michael J. Landzberg, Jane W. Newburger, Christopher SD Almond, Children's 
Hospital Boston, Boston, MA, Harvard Medical School, Boston, MA
Background: Elevations in serum cardiac troponins have been found to occur in runners
completing long distances.Our objectives were to determine prevalence of and risk fac-
tors for troponin elevations in marathon finishers.
Methods: Entrants in the 2002 Boston Marathon were recruited the weekend prior to the
race, at which time we obtained demographic, health history, and training data. At race
completion, we obtained race performance data and serum third-generation troponin T
(cTnT) and I (cTnI) levels. Potential risk factors for troponin elevations were selected a
priori from clinical suspicion and literature review and were evaluated using logistic
regression analysis.
Results: A total of 482 runners completed surveys and had labs drawn. In all, 33% were
female, 20% were aged <30 years, and 92% had run at least one prior marathon. Com-
pared to males, females were significantly younger (p<0.001), slower (p<0.001), and less
experienced marathoners (p=0.018). The majority of marathon runners in our cohort
(68%) had some degree of troponin elevation after completing the marathon (cTnT>0.01
ng/mL or cTnI>0.1 ng/mL); of these, 55 (17%) had significant elevations (cTnT >0.075
ng/mL or cTnI>0.5 ng/mL). On multivariate analysis, individuals at greatest risk of signifi-
cant troponin elevations were less experienced marathoners (<5 prior marathons run,
O.R. 3.3, 95% C.I. 1.6-6.6, p<0.001) and younger runners (<30 years, O.R. 2.4, 95% C.I.
1.3-4.5 p=0.006). Female gender was a univariate but not multivariate correlate, and
health history, anthropometrics, family history, training intensity, and race performance
were not associated. Young age and marathon inexperience were robust predictors of
troponin elevations over a broad range of threshold values analyzed and with troponins
evaluated as continuous variables.
Conclusion: In a large and athletically diverse group of marathon finishers, we found that
significant troponin elevations were common, and that less experienced marathoners and
younger runners were at greatest risk of experiencing elevations. Further prospective
research by our group into potential clinical significance of these findings is ongoing.
2:30 p.m.
408-3 Quantitative Detection of Inflammation in Carotid 
Atherosclerosis by Dynamic Contrast Enhanced 
Magnetic Resonance Imaging
William S. Kerwin, Marina Ferguson, Kevin O'Brien, Thomas Hatsukami, Chun Yuan, 
University of Washington, Seattle, WA
Background: Inflammation in advanced atherosclerotic plaque is a primary catalyst for
disruption of the plaque and subsequent thromboembolic events. Thus, a quantitative,
non-invasive technique for characterizing inflammation would be invaluable for detecting
vulnerable, inflamed plaques and monitoring therapeutic response. We hypothesize that
the dynamic response of magnetic resonance imaging (MRI) to an injected gadolinium
contrast agent can be used for quantitative evaluation of inflammation by measuring the
transfer constant Ktrans between the blood plasma and the extracellular space. This
parameter is derived from the curve of enhancement vs. time and quantifies the
increased vascularity, permeability, and extracellular water content associated with the
inflammatory response.
Methods: The association of Ktrans with macrophages, the predominant inflammatory
cells in human carotid atherosclerotic plaque, was evaluated in 18 carotid endarterec-
tomy patients. Within one week prior to surgery, cross-sectional MRI scans centered at
the carotid bifurcation of each patient were performed using a dynamic protocol (fast
spoiled gradient echo; 15 seconds per image; 10 time frames), which included injection
of 0.1 mmol/kg of a standard, low molecular weight gadolinium contrast agent. Kinetic
modelling of the MRI results was used to estimate Ktrans and the fractional plasma vol-
ume vp of the plaque. After surgery, the endarterectomy specimens were sectioned,
matched to the MRI results, and double-stained for macrophages (HAM56) and vascular
endothelial cells (Ulex, to mask cross-labelling by HAM56). The relative area of each
specimen staining positive for macrophages was measured and normalized by the total
plaque area.
Results: Macrophage content of the excised specimens was found to correlate strongly
with Ktrans (R= 0.74, p=0.0005) as measured by MRI.
Conclusion: Ktrans serves as a powerful marker of inflammation for clinical evaluation of
atherosclerotic plaque. The strong correlation suggests it can be used to measure thera-
peutic response aimed at reducing plaque inflammation.
